Dizal Unveils Groundbreaking Hematologic Cancer Therapies at EHA and ICML 2025 Dizal Pharmaceutical showcases two innovative treatments, golidocitinib and DZD8586, presenting their promising results in hematologic malignancies at major international conferences.

Dizal Unveils Groundbreaking Hematologic Cancer Therapies at EHA and ICML 2025 #None #DZD8586 #Dizal #Golidocitinib

Dizal to Showcase Drug Advances in Hematologic and Lung Cancers at ASCO 2025 Dizal Pharmaceutical plans to present outstanding results of its innovative therapies for hematological malignancies and lung cancer at ASCO 2025.

Dizal to Showcase Drug Advances in Hematologic and Lung Cancers at ASCO 2025 #China #Shanghai #DZD8586 #Dizal #DZD6008

Dizal Unveils Promising Clinical Results for Lymphoma Treatments at Upcoming Global Conferences Dizal will showcase recent clinical data on golidocitinib and DZD8586, targeting lymphoma treatments, at major international hematology conferences.

Dizal Unveils Promising Clinical Results for Lymphoma Treatments at Upcoming Global Conferences #China #Shanghai #DZD8586 #Dizal #Golidocitinib

Dizal to Present Innovative Data on Cancer Treatments at ASCO 2025 Dizal will reveal groundbreaking studies in hematologic cancers and lung cancer treatment at the ASCO 2025 conference, focusing on their innovative drugs DZD8586 and DZD6008.

Dizal to Present Innovative Data on Cancer Treatments at ASCO 2025 #China #Shanghai #DZD8586 #Dizal #DZD6008

Dizal Unveils Promising DZD8586 Data at 2024 ASH Annual Meeting for B-cell Non-Hodgkin Lymphoma Dizal has presented new findings on DZD8586, a LYN/BTK dual inhibitor, showing its efficacy and safety for B-NHL at the recent ASH Meeting.

Dizal Unveils Promising DZD8586 Data at 2024 ASH Annual Meeting for B-cell Non-Hodgkin Lymphoma #China #Shanghai #DZD8586 #Dizal #B-cell_Lymphoma